Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.

导出原文传递

翻译打印收藏纠错

第一作者： Andrea,Duminuco

第一单位： Division of Hematology and BMT Unit, A.O.U. Policlinico G.Rodolico-San Marco, Catania, Italy.

作者： Andrea,Duminuco ^[1] ; Antonella,Nardo ^[1] ; Alessandra,Orofino ^[1] ; Giuliana,Giunta ^[1] ; Concetta,Conticello ^[1] ; Vittorio,Del Fabro ^[1] ; Annalisa,Chiarenza ^[1] ; Marina S,Parisi ^[1] ; Amalia,Figuera ^[1] ; Salvatore,Leotta ^[1] ; Giuseppe,Milone ^[1] ; Alessandra,Cupri ^[1] ; Daniela,Cambria ^[1] ; Francesco,Di Raimondo ^[2] ; Alessandra,Romano ^[2] ; Giuseppe A,Palumbo ^[3]

作者单位： Division of Hematology and BMT Unit, A.O.U. Policlinico G.Rodolico-San Marco, Catania, Italy. ^[1] Division of Hematology and BMT Unit, A.O.U. Policlinico G.Rodolico-San Marco, Catania, Italy.;Dipartimento di Specialità Medico-Chirurgiche, CHIRMED, Sezione di Ematologia University of Catania, Catania, Italy. ^[2] Division of Hematology and BMT Unit, A.O.U. Policlinico G.Rodolico-San Marco, Catania, Italy.;Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate G.F. Ingrassia, University of Catania, Catania, Italy. ^[3]

关键词 SARS-CoV-2 breakthrough infection hematological diseases immunocompromised patients prophylaxis tixagevimab-cilgavimab

主题词人类(Humans);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);血液病(Hematologic Diseases)

DOI 10.1002/cncr.35005

PMID 37658645

发布时间 2024-03-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交